TrialThe Lancet. Respiratory medicine2025

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

Claire Keating et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.